Plan B OTC Switch Delay Will Allow Review Of Teenage Use Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Rep. Sam Farr (D-Calif.) expressed concern that the review delay was due to political pressure. Crawford says the delay was prompted by regulatory, not political issues.
You may also be interested in...
Battle Over Plan B In Virginia Coincides With User Fee Extension
Legislation being considered by Virginia legislature seeks to limit distribution of emergency contraception. FDA has delayed its decision to switch "morning-after" pill Plan B to OTC status.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis' Once-Daily Allegra-D To Launch Mid-Year
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).